Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases

Xiang Fang, P. Singh, R. G. Smith

Research output: Contribution to journalArticle

Abstract

Arachidonic acid is metabolized to epoxyeicosatrienoic acids (EETs) by cytochrome P450 epoxygenase. Four EET regioisomers, 5,6-, 8,9-, 11,12- and 14,15-EETs, are formed depending on the location of the epoxy group. EETs can function as endothelium-derived hyperpolarizing factors in many vascular beds, and they also promote angiogenesis and inhibit inflammatory processes and platelet aggregation. EETs are rapidly converted to their corresponding less bioactive diols by soluble epoxide hydrolase (sEH). Inhibition of the degradation of EETs provides protection against injuries related to vascular dysfunction, inflammation and reactive oxygen species. Therefore, sEH has been proposed as a therapeutic target in the treatment of many vascular diseases, such as hypertension, myocardial infarction, renal diseases and ischemic stroke. In this regard, several potent and selective sEH inhibitors have been developed and proven effective in experimental models of vascular diseases.

Original languageEnglish (US)
Pages (from-to)579-585
Number of pages7
JournalDrugs of the Future
Volume34
Issue number7
DOIs
StatePublished - 2009

Fingerprint

Epoxide Hydrolases
Cardiovascular Diseases
Vascular Diseases
Blood Vessels
Platelet Aggregation
Arachidonic Acid
Cytochrome P-450 Enzyme System
Endothelium
Reactive Oxygen Species
Theoretical Models
Therapeutics
Stroke
Myocardial Infarction
Hypertension
Inflammation
Kidney
Acids
Wounds and Injuries

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. / Fang, Xiang; Singh, P.; Smith, R. G.

In: Drugs of the Future, Vol. 34, No. 7, 2009, p. 579-585.

Research output: Contribution to journalArticle

Fang, Xiang ; Singh, P. ; Smith, R. G. / Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. In: Drugs of the Future. 2009 ; Vol. 34, No. 7. pp. 579-585.
@article{cc8673bf0e5348cbb55d0f0aeda5177d,
title = "Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases",
abstract = "Arachidonic acid is metabolized to epoxyeicosatrienoic acids (EETs) by cytochrome P450 epoxygenase. Four EET regioisomers, 5,6-, 8,9-, 11,12- and 14,15-EETs, are formed depending on the location of the epoxy group. EETs can function as endothelium-derived hyperpolarizing factors in many vascular beds, and they also promote angiogenesis and inhibit inflammatory processes and platelet aggregation. EETs are rapidly converted to their corresponding less bioactive diols by soluble epoxide hydrolase (sEH). Inhibition of the degradation of EETs provides protection against injuries related to vascular dysfunction, inflammation and reactive oxygen species. Therefore, sEH has been proposed as a therapeutic target in the treatment of many vascular diseases, such as hypertension, myocardial infarction, renal diseases and ischemic stroke. In this regard, several potent and selective sEH inhibitors have been developed and proven effective in experimental models of vascular diseases.",
author = "Xiang Fang and P. Singh and Smith, {R. G.}",
year = "2009",
doi = "10.1358/dof.2009.034.07.1391872",
language = "English (US)",
volume = "34",
pages = "579--585",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "7",

}

TY - JOUR

T1 - Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases

AU - Fang, Xiang

AU - Singh, P.

AU - Smith, R. G.

PY - 2009

Y1 - 2009

N2 - Arachidonic acid is metabolized to epoxyeicosatrienoic acids (EETs) by cytochrome P450 epoxygenase. Four EET regioisomers, 5,6-, 8,9-, 11,12- and 14,15-EETs, are formed depending on the location of the epoxy group. EETs can function as endothelium-derived hyperpolarizing factors in many vascular beds, and they also promote angiogenesis and inhibit inflammatory processes and platelet aggregation. EETs are rapidly converted to their corresponding less bioactive diols by soluble epoxide hydrolase (sEH). Inhibition of the degradation of EETs provides protection against injuries related to vascular dysfunction, inflammation and reactive oxygen species. Therefore, sEH has been proposed as a therapeutic target in the treatment of many vascular diseases, such as hypertension, myocardial infarction, renal diseases and ischemic stroke. In this regard, several potent and selective sEH inhibitors have been developed and proven effective in experimental models of vascular diseases.

AB - Arachidonic acid is metabolized to epoxyeicosatrienoic acids (EETs) by cytochrome P450 epoxygenase. Four EET regioisomers, 5,6-, 8,9-, 11,12- and 14,15-EETs, are formed depending on the location of the epoxy group. EETs can function as endothelium-derived hyperpolarizing factors in many vascular beds, and they also promote angiogenesis and inhibit inflammatory processes and platelet aggregation. EETs are rapidly converted to their corresponding less bioactive diols by soluble epoxide hydrolase (sEH). Inhibition of the degradation of EETs provides protection against injuries related to vascular dysfunction, inflammation and reactive oxygen species. Therefore, sEH has been proposed as a therapeutic target in the treatment of many vascular diseases, such as hypertension, myocardial infarction, renal diseases and ischemic stroke. In this regard, several potent and selective sEH inhibitors have been developed and proven effective in experimental models of vascular diseases.

UR - http://www.scopus.com/inward/record.url?scp=84930541884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930541884&partnerID=8YFLogxK

U2 - 10.1358/dof.2009.034.07.1391872

DO - 10.1358/dof.2009.034.07.1391872

M3 - Article

AN - SCOPUS:84930541884

VL - 34

SP - 579

EP - 585

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 7

ER -